<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63592">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01682837</url>
  </required_header>
  <id_info>
    <org_study_id>LiqKMgCit-1208-01</org_study_id>
    <nct_id>NCT01682837</nct_id>
  </id_info>
  <brief_title>Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension</brief_title>
  <official_title>Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meta Pharm Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Meta Pharm Development, LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liquid potassium-magnesium citrate (KMgCit) as a pharmaceutical formulation will lower blood
      pressure among patients with pre- or Stage I hypertension on their customary diet.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this protocol, the investigators want to explore whether KMgCit taken during a customary
      dietary setting, might serve as a &quot;surrogate&quot; for the DASH diet to lower blood pressure.
      This study has obvious biomedical importance. Lifestyle modifications are often recommended
      for pre- or Stage I hypertension. The DASH diet is such a modification that has been shown
      to be effective. However, this diet is costly and difficult to adhere to long-term. If
      KMgCit were shown to be effective in lowering blood pressure, it would provide a safe and
      convenient alternative to the DASH diet.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>24-hour blood pressure</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Office blood pressure</measure>
    <time_frame>2 and 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum C-terminal telopeptide (CTX)</measure>
    <time_frame>2 and 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour urinary calcium</measure>
    <time_frame>4 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid to femoral pulse wave velocity</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central aortic blood pressure</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will comprise microcrystalline cellulose, equivalent in volume in each sachet as other test products. Subjects will dissolve the entire content of a sachet in 250 ml water and drink it with breakfast and again with dinner for a total of 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Potassium chloride powder</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Potassium chloride powder, identical in appearance to potassium citrate powder, will contain 20 meq KCl per sachet. Subjects will dissolve the content of each sachet in 250 ml water and ingest it with breakfast and again with dinner, to deliver 40 meq K (as chloride) per day for a total of 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Potassium citrate powder</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Potassium citrate powder will contain 20 meq KCl per sachet. Subjects will dissolve the content of each sachet in 250 ml water and ingest it with breakfast and again with dinner, to deliver 40 meq K (as citrate) per day for a total of 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Potassium magnesium citrate powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Potassium magnesium citrate will be prepared by mixing potassium citrate, magnesium citrate and/or citric acid. The content of each sachet will be dissolved in 250 ml water and will be drunk with breakfast and again with dinner to deliver 40 meq K, 20 meq Mg and 74 meq citrate per day for a total of 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Potassium chloride powder</intervention_name>
    <description>1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks</description>
    <arm_group_label>Potassium chloride powder</arm_group_label>
    <other_name>KCl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Potassium citrate powder</intervention_name>
    <description>1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks</description>
    <arm_group_label>Potassium citrate powder</arm_group_label>
    <other_name>KCit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Potassium magnesium citrate powder</intervention_name>
    <description>1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks</description>
    <arm_group_label>Potassium magnesium citrate powder</arm_group_label>
    <other_name>KMgCit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 sachet mixed with 250 ml water given at breakfast and dinner, for a total of 2 sachets/day, for 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Microcystalline cellulose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women &gt; 21 years of age

          -  Any Race/Ethnicity

          -  Pre- or Stage I hypertension (BP &gt;= 120/80 and &lt;= 159/99)

        Exclusion Criteria:

          -  Diabetes mellitus

          -  Renal impairment (serum creatinine &gt; 1.4 mg/dL)

          -  Any heart diseases such as congestive heart failure or sustained arrhythmia

          -  Chronic NSAID use

          -  Treatment with diuretics

          -  Gastroesophageal reflux disease (GERD) requiring treatment with acid reducing agents
             or antacid more than once a week

          -  Esophageal-gastric ulcer

          -  Chronic diarrhea

          -  Hyperkalemia (serum &gt; 4.6 mEq/L for patients on ACE inhibitors or ARBs, serum K &gt; 5.0
             for patient not on ACE inhibitors or ARBs)

          -  Abnormal liver function test (AST or ALT above upper limit of normal range)

          -  Subjects who require any potassium supplement on a regular basis from any reasons

          -  Pregnancy

          -  History of major depression, bipolar disorder, or schizophrenia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wanpen Vongpatanasin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Debbie Arbique, DNP</last_name>
    <phone>214-648-2968</phone>
    <email>debbie.arbique@utsouthwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hypertension Clinic - UT Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Arbique, DNP</last_name>
      <phone>214-648-2968</phone>
      <email>Debbie.Arbique@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Wanpen Vongpatanasin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 29, 2012</lastchanged_date>
  <firstreceived_date>September 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Magnesium citrate</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
